Profile
Peter J.
Langecker served as President, Chief Executive Officer & Director at Oncotelic Therapeutics, Inc. from 2009 to 2014.
Prior to that, he was a Director at Xcyte Therapies, Inc. from 1999 to 2006 and Vice President-Clinical Affairs at Sugen, Inc. from 1997 to 1999.
He also held positions as Director-Clinical Research at Schering-Plough Corp.
and Vice President-Clinical Research at Coulter Pharmaceuticals, Inc. Additionally, he served as Chief Medical Officer at DURECT Corp.
from 2006 to 2009 and Chief Medical Officer & VP-Clinical Affairs at Intarcia Therapeutics, Inc. from 1999 to 2006.
Dr. Langecker earned a doctorate degree from Ludwig-Maximilians-Universität München.
Former positions of Peter J. Langecker
| Companies | Position | End |
|---|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Chief Executive Officer | 2014-05-14 |
| DURECT CORPORATION | Chief Tech/Sci/R&D Officer | 2009-06-15 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Chief Tech/Sci/R&D Officer | 2006-03-31 |
| Xcyte Therapies, Inc. | Director/Board Member | 2006-03-29 |
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | 1998-12-31 |
Training of Peter J. Langecker
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ONCOTELIC THERAPEUTICS, INC. | Health Technology |
| DURECT CORPORATION | Health Technology |
| CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Sugen, Inc.
Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
Coulter Pharmaceuticals, Inc.
 Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
| Xcyte Therapies, Inc. | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Peter J. Langecker
